A healthy lifestyle and appropriate medications can help people with heart disease live longer and avoid a heart attack or stroke, according to new...

AstraZeneca PLC's (AZN) key new heart drug, Brilinta, has secured final approval by the U.K.'s health-care cost-effectiveness regulator for use on...

AstraZeneca PLC (AZN) Monday said trial data showed its new blood thinner pill Brilinta was associated with fewer deaths of patients who had...

NEW YORK (Reuters Health) - A new study suggests Americans with heart failure may benefit less from recommended medications than patients in other countries.The findings, which one doctor called "provocative," point to an emerging problem in drug development: As research becomes increasingly ...

U.K.-based AstraZeneca PLC (AZN) Thursday raised its earnings guidance despite producing a flat second-quarter net profit that missed forecasts, as ...

LONDON (Reuters) - AstraZeneca Plc has no plans to run a clinical trial to confirm the reasons behind a discrepancy between the performance of its newly approved heart drug Brilinta in North America and other parts of the world.Some analysts have speculated ...

LONDON (Reuters) - AstraZeneca shares jumped 3.5 percent on Thursday, buoyed by U.S. approval for its new heart drug Brilinta as a rival to Plavix, the world's second-biggest selling medicine.But industry analysts warned the London-based drugmaker still had a ...

Please disregard the latest headlines on the FDA's approval of AstraZeneca's BRILINTA tablets. The news was reported in full at 1322 GMT Wednesday...

Posted on 07/20/11 at 5:11pm by Louis Bedigian . AstraZeneca (NYSE: AZN ) spiked 1% this afternoon following rumors that Brilinta has received FDA...

"FDA Grills AstraZeneca for More Brilinta Drug Data Before Ap" is categorized as "business". This video was licensed from Grab Networks. The...